Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection

D. D. Richman, J. Andrews, Margaret A Fischl, J. Patrone-Reese, L. Dearmas, J. Santangelo, C. J. Kennedy, J. A. McCutchan, S. A. Spector, M. H. Grieco, A. Englard, G. F. McKinlay, M. S. Gottlieb, Y. Bryson, S. Chafey, J. Lederman, P. A. Voldberding, R. Wong, M. Nash

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Zidovudine (AZT, 3'-azido-3'-deoxythymidine) was shown in a controlled trial to decrease the incidence of mortality, reduce the frequency of opportunistic infections, and provide other clinical benefits to patients with acquired immune deficiency syndrome (AIDS) and advanced AIDS-related complex. Two hundred twenty-nine patients who participated in the double-blind placebo-controlled trial of zidovudine were enrolled in an open-label study. As of August 31, 1987, an interim analysis indicated that patients receiving zidovudine continued to derive benefits from therapy. Surivival rates of zidovudine-treated patients were higher than those that might have been expected from previous experience with similar patients. Patients continued to experience episodes of opportunistic infections; however, these infections were either of decreased severity or were more responsive to conventional therapy. The increase in median CD4 cell counts that occurred initially was followed by a gradual decline to near baseline values. Hematologic toxicities continued to be the major laboratory abnormality associated with drug administration; however, new or more frequent toxicity was not observed with more prolonged therapy. Progressive bone marrow suppression did not appear to be associated with prolonged administration. Overall, patients originally enrolled in the double-blind trial continued to receive clinical benefit from zidovudine therapy.

Original languageEnglish
Pages (from-to)208-213
Number of pages6
JournalAmerican Journal of Medicine
Volume85
Issue number2 A
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Zidovudine
Virus Diseases
Placebos
HIV
Opportunistic Infections
Acquired Immunodeficiency Syndrome
Therapeutics
CD4 Lymphocyte Count
Bone Marrow
Mortality
Incidence
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection. / Richman, D. D.; Andrews, J.; Fischl, Margaret A; Patrone-Reese, J.; Dearmas, L.; Santangelo, J.; Kennedy, C. J.; McCutchan, J. A.; Spector, S. A.; Grieco, M. H.; Englard, A.; McKinlay, G. F.; Gottlieb, M. S.; Bryson, Y.; Chafey, S.; Lederman, J.; Voldberding, P. A.; Wong, R.; Nash, M.

In: American Journal of Medicine, Vol. 85, No. 2 A, 01.01.1988, p. 208-213.

Research output: Contribution to journalArticle

Richman, DD, Andrews, J, Fischl, MA, Patrone-Reese, J, Dearmas, L, Santangelo, J, Kennedy, CJ, McCutchan, JA, Spector, SA, Grieco, MH, Englard, A, McKinlay, GF, Gottlieb, MS, Bryson, Y, Chafey, S, Lederman, J, Voldberding, PA, Wong, R & Nash, M 1988, 'Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection', American Journal of Medicine, vol. 85, no. 2 A, pp. 208-213.
Richman, D. D. ; Andrews, J. ; Fischl, Margaret A ; Patrone-Reese, J. ; Dearmas, L. ; Santangelo, J. ; Kennedy, C. J. ; McCutchan, J. A. ; Spector, S. A. ; Grieco, M. H. ; Englard, A. ; McKinlay, G. F. ; Gottlieb, M. S. ; Bryson, Y. ; Chafey, S. ; Lederman, J. ; Voldberding, P. A. ; Wong, R. ; Nash, M. / Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection. In: American Journal of Medicine. 1988 ; Vol. 85, No. 2 A. pp. 208-213.
@article{320be1c2983e45e5b93c9adb504dfc8c,
title = "Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection",
abstract = "Zidovudine (AZT, 3'-azido-3'-deoxythymidine) was shown in a controlled trial to decrease the incidence of mortality, reduce the frequency of opportunistic infections, and provide other clinical benefits to patients with acquired immune deficiency syndrome (AIDS) and advanced AIDS-related complex. Two hundred twenty-nine patients who participated in the double-blind placebo-controlled trial of zidovudine were enrolled in an open-label study. As of August 31, 1987, an interim analysis indicated that patients receiving zidovudine continued to derive benefits from therapy. Surivival rates of zidovudine-treated patients were higher than those that might have been expected from previous experience with similar patients. Patients continued to experience episodes of opportunistic infections; however, these infections were either of decreased severity or were more responsive to conventional therapy. The increase in median CD4 cell counts that occurred initially was followed by a gradual decline to near baseline values. Hematologic toxicities continued to be the major laboratory abnormality associated with drug administration; however, new or more frequent toxicity was not observed with more prolonged therapy. Progressive bone marrow suppression did not appear to be associated with prolonged administration. Overall, patients originally enrolled in the double-blind trial continued to receive clinical benefit from zidovudine therapy.",
author = "Richman, {D. D.} and J. Andrews and Fischl, {Margaret A} and J. Patrone-Reese and L. Dearmas and J. Santangelo and Kennedy, {C. J.} and McCutchan, {J. A.} and Spector, {S. A.} and Grieco, {M. H.} and A. Englard and McKinlay, {G. F.} and Gottlieb, {M. S.} and Y. Bryson and S. Chafey and J. Lederman and Voldberding, {P. A.} and R. Wong and M. Nash",
year = "1988",
month = "1",
day = "1",
language = "English",
volume = "85",
pages = "208--213",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "2 A",

}

TY - JOUR

T1 - Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection

AU - Richman, D. D.

AU - Andrews, J.

AU - Fischl, Margaret A

AU - Patrone-Reese, J.

AU - Dearmas, L.

AU - Santangelo, J.

AU - Kennedy, C. J.

AU - McCutchan, J. A.

AU - Spector, S. A.

AU - Grieco, M. H.

AU - Englard, A.

AU - McKinlay, G. F.

AU - Gottlieb, M. S.

AU - Bryson, Y.

AU - Chafey, S.

AU - Lederman, J.

AU - Voldberding, P. A.

AU - Wong, R.

AU - Nash, M.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Zidovudine (AZT, 3'-azido-3'-deoxythymidine) was shown in a controlled trial to decrease the incidence of mortality, reduce the frequency of opportunistic infections, and provide other clinical benefits to patients with acquired immune deficiency syndrome (AIDS) and advanced AIDS-related complex. Two hundred twenty-nine patients who participated in the double-blind placebo-controlled trial of zidovudine were enrolled in an open-label study. As of August 31, 1987, an interim analysis indicated that patients receiving zidovudine continued to derive benefits from therapy. Surivival rates of zidovudine-treated patients were higher than those that might have been expected from previous experience with similar patients. Patients continued to experience episodes of opportunistic infections; however, these infections were either of decreased severity or were more responsive to conventional therapy. The increase in median CD4 cell counts that occurred initially was followed by a gradual decline to near baseline values. Hematologic toxicities continued to be the major laboratory abnormality associated with drug administration; however, new or more frequent toxicity was not observed with more prolonged therapy. Progressive bone marrow suppression did not appear to be associated with prolonged administration. Overall, patients originally enrolled in the double-blind trial continued to receive clinical benefit from zidovudine therapy.

AB - Zidovudine (AZT, 3'-azido-3'-deoxythymidine) was shown in a controlled trial to decrease the incidence of mortality, reduce the frequency of opportunistic infections, and provide other clinical benefits to patients with acquired immune deficiency syndrome (AIDS) and advanced AIDS-related complex. Two hundred twenty-nine patients who participated in the double-blind placebo-controlled trial of zidovudine were enrolled in an open-label study. As of August 31, 1987, an interim analysis indicated that patients receiving zidovudine continued to derive benefits from therapy. Surivival rates of zidovudine-treated patients were higher than those that might have been expected from previous experience with similar patients. Patients continued to experience episodes of opportunistic infections; however, these infections were either of decreased severity or were more responsive to conventional therapy. The increase in median CD4 cell counts that occurred initially was followed by a gradual decline to near baseline values. Hematologic toxicities continued to be the major laboratory abnormality associated with drug administration; however, new or more frequent toxicity was not observed with more prolonged therapy. Progressive bone marrow suppression did not appear to be associated with prolonged administration. Overall, patients originally enrolled in the double-blind trial continued to receive clinical benefit from zidovudine therapy.

UR - http://www.scopus.com/inward/record.url?scp=0023722757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023722757&partnerID=8YFLogxK

M3 - Article

C2 - 3044087

AN - SCOPUS:0023722757

VL - 85

SP - 208

EP - 213

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 2 A

ER -